DataVXSmallPaper
journal article·2022-03Open access

Targeted Nanoparticle for Co‐delivery of HER2 siRNA and a Taxane to Mirror the Standard Treatment of HER2+ Breast Cancer: Efficacy in Breast Tumor and Brain Metastasis (Small 11/2022)

Worapol Ngamcherdtrakul, Daniel S. Bejan, William Cruz‐Muñoz, Moataz Reda, Husam Y. Zaidan, Natnaree Siriwon, Suphalak Marshall, Ruijie Wang, Molly A. Nelson, Justin P. C. Rehwaldt, Joe W. Gray, Kullervo Hynynen, Wassana Yantasee

Small· Volume 18· Issue 11
Publisher pageOpen full text
Source abstract

Abstract

Breast Cancer Treatment In article number 2107550, Wassana Yantasee and co-workers develop polymer-decorated mesoporous silica nanoparticles for HER2-positive breast cancer treatment. This patented versatile platform can co-deliver multiple therapeutic classes to ensure that they reach the target cells at the same time to fully realize their synergy. Illustrated herein are nanoparticles with three drug cargos: HER2 antibody, HER2 siRNA, and chemotherapeutic docetaxel.
Source: openalex_inverted_index · Quality: baseline

Research context

PolymersNanomaterials

OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · Advanced Biosensing Techniques and Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

PDX Pharmaceuticals Inc. 3303 S Bond Ave, CH13B Portland OR 97239 USA

Sunnybrook Research Institute 2075 Bayview Ave Toronto ON M4N 3M5 Canada

Department of Biomedical Engineering Oregon Health & Science University 3303 S Bond Ave Portland OR 97239 USA

Department of Radiology and Institute of Biomedical Engineering Faculty of Medicine Prince of Songkla University 15 Karnjanavanich Road Hat Yai Songkhla 90110 Thailand

Department of Medical Biophysics Institute of Biomedical Engineering University of Toronto 2075 Bayview Ave Toronto ON M4N 3M5 Canada

References

Reference metadata was not supplied for this record.